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Abstract: A history of infectious mononucleosis (IM), symptomatic primary infection with the 
Epstein Barr virus, is associated with the development of autoimmune diseases and increases the 
risk to develop multiple sclerosis. Here, we hypothesized that immune activation during IM 
triggers autoreactive immune responses. Antibody responses towards cellular antigens using a 
HEp-2 based indirect immunofluorescence assay and native myelin oligodendrocyte glycoprotein 
(MOG) using a flow cytometry-based assay were determined in 35 patients with IM and in 23 
control subjects. We detected frequent immunoglobulin M (IgM) reactivity to vimentin, a major 
constituent of the intermediate filament family of proteins, in IM patients (27/35; 77%) but rarely in 
control subjects (2/23; 9%). IgG autoantibodies binding to HEp-2 cells were absent in both groups. 
In contrast, IgG responses to native MOG, present in up to 40% of children with inflammatory 
demyelinating diseases of the central nervous system (CNS), were detectable in 7/35 (20%) patients 
with IM but not in control subjects. Normalization of anti-vimentin IgM levels to increased total 
IgM concentrations during IM resulted in loss of significant differences for anti-vimentin IgM 
titers. Anti-MOG specific IgG responses were still detectable in a subset of three out of 35 patients 
with IM (9%), even after normalization to increased total IgG levels. Vimentin-specific IgM and 
MOG-specific IgG responses decreased following clinical resolution of acute IM symptoms. We 
conclude from our data that MOG-specific memory B cells are activated in subset of patients with 
IM.  
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1. Introduction 
Epstein-Barr virus (EBV) is a gamma-herpesvirus that establishes a benign, lifelong infection in 
resting memory B cells in over 90% of the human population worldwide. In the industrialized 
world, about 50% of the population acquires EBV between one and five years of age, while another 
large percentage contracts the virus during adolescence [1]. Up to 77% of individuals, who acquire 
EBV in the second life decade or later, manifest symptomatic primary infection, known as infectious 
mononucleosis (IM) [2].  EBV infection, and in particular a history of IM, have been associated with 
the development of autoimmune diseases [3]. Several well-controlled epidemiological studies 
confirmed that a history of IM is associated with an approximately two-fold increased risk to 
develop multiple sclerosis (MS) later in life [3,4].  In addition, EBV seropositivity occurs more 
frequently in patients with systemic lupus erythematosus (SLE) compared to demographically 
matched healthy controls [5] and juvenile forms of these diseases appear to be particularly 
associated with EBV [6,7].  
We hypothesized that strong immune activation during IM facilitates activation and expansion 
of autoreactive lymphocytes, thereby lowering the threshold for breakdown of self-tolerance to 
autoantigens. Therefore, we profiled autoreactive immunoglobulin M (IgM) and IgG responses to a 
panel of autoimmune disease-associated antigens in patients with IM. 
2. Materials and Methods 
Autoreactive antibody responses were determined in two independent cohorts of a total  
of 35 patients with IM and in 23 control subjects matched by age and gender (Table 1). Patients were 
recruited at the Department of Pediatrics, University Hospital Zurich (Zurich, Switzerland)  
(cohort 1) and Innsbruck (Austria) (cohort 2). Control subjects recruited in cohort 1 consisted of 
children with acute symptoms compatible with IM (fatigue, fever, sore throat, cervical 
lymphadenopathy) but seronegative for EBV-derived viral capsid antigen (VCA)-specific IgM and 
seropositive for EBV-derived nuclear antigen 1 (EBNA1)-specific IgG indicating acute upper 
respiratory tract but past EBV infection. Control subjects recruited in cohort 2 consisted of children 
with non-inflammatory diseases (migraine and other types of headaches not associated with 
inflammatory conditions and attention deficit hyperactivity disorder). The study was approved by 
the local Institutional Review Board (IRB StV29/06 University of Zurich, IRB AM4059 University of 
Innsbruck), and all subjects and/or their guardians provided informed consent. Blood samples were 
drawn at hospital admission, which was 3–28 days after onset of illness (Table 1). Samples derived 
from IM patients and controls in each cohort were obtained using the same procedures and stored 
under the same conditions. Heterophile antibodies of the IgM type directed against mammalian 
erythrocytes are associated with IM (Paul-Bunnell reaction), but their determination can result in 
false-negative and false-positive results. Here, IM was diagnosed based on the clinical presentation, 
presence of anti-VCA IgM antibodies and lack of IgG antibodies specific for EBNA1. Free viral 
DNA was detectable in all serum samples derived from IM patients but in none of the control 
samples.  
IgM and IgG responses to cellular antigens were determined using a Hep-2 based  
indirect immunofluorescence assay. IgM responses to vimentin were quantified by  
enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s recommendation 
(Vidia Ltd., Jesenice, Czech Republic). IgG responses to myelin oligodendrocyte glycoprotein 
(MOG) were determined using a fluorescence-activated cell sorting (FACS) live cell-based assay as 
described previously [9,10]. In brief, human oligodendroglial MO3.13 cells, which expresses 
phenotypic characteristics of primary oligodendrocytes, were transduced to express full-length 
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human MOG [9]. Serum samples were incubated with MO3.13MOG+ cells which were 
subsequently stained with an Alexa Fluor 488-labeled goat anti-human IgG secondary antibody 
(Thermo Fisher Scientific, Reinach, Switzerland) [9,11]. Analysis of cell surface staining was 
determined by flow cytometry and  
MOG-specific IgG titers were defined by subtraction of mean of the fluorescence intensity (MFI) 
obtained with non-transduced MO3.13 control cells from the MFI obtained with transduced MO3.13 
MOG+ cells (ΔMFI) [9,10]. The cutoff was set to 3 standard deviations above the mean ΔMFI of 
pediatric controls and samples were considered positive if they were above threshold at least 2 
times out of 3 repeated experiments [9,11].  
Table 1. Demographical characteristics of patients and control subjects. 
 Cohort 1 Cohort 2 
 Controls IM patients Controls IM patients 
Number  10 22 13 13 
Gender (f/m) 6/4 11/11 9/4 5/8 
Median Age (Range) 9.5 (3-15) 12 (2-15) 16 (8-18) 16 (7-18) 
Duration of Symptoms NA 7-28 days NA 3-21 days 
3. Results 
MOG-specific IgG antibody responses were detected in a subgroup of IM patients (n = 7/35) 
but in none of the control subjects (n = 0/23) (Figure 1A,B). To evaluate whether MOG-specific IgG 
responses would remain elevated following clinical resolution of acute IM symptoms, we 
additionally determined antibody responses six months after onset of IM in cohort 1, in which 
samples from 11/22 patients were obtained longitudinally. MOG-specific IgG responses decreased 
in all patients and fell below cut off levels in those patients who exhibited positive MOG-specific 
responses during acute IM (Figure 1C). Thus, IgG antibodies specific for native MOG, indicative for 
central nervous system (CNS) demyelinating diseases in children, are transiently increased in a 
subgroup of patients with IM. None of the patients developed a clinical phenotype reminiscent of 
MOG-IgG-associated diseases such as acute disseminated encephalomyelitis (ADEM), MS, 
aquaporin-4-seronegative neuromyelitis optica spectrum disorder (NMOSD), isolated optic neuritis 
or transverse myelitis, or bilateral optic neuritis (BON) within the observation period of six months 
after onset of acute IM. 
Using a Hep-2 based indirect immunofluorescence assay, we detected frequent IgM reactivity 
to reticular cytoplasmic antigens reminiscent of vimentin exclusively in IM patients (27/35; 77%) but 
rarely in control subjects (2/23; 9%) (Figure 2A,B). IgG autoantibodies binding to HEp-2 cells were 
absent in both groups. IgM reactivity towards vimentin could be confirmed by ELISA in both IM 
cohorts (Figure 2C,D). Longitudinal analysis of anti-vimentin IgM reactivity showed that these 
antibodies fell below the detection limit of the ELISA six months following acute IM in almost all 
patients studied (10/11; 91%). Thus, patients with acute IM showed elevated MOG-specific IgG and 
vimentin-specific IgM responses as compared with children with acute upper respiratory tract 
infections not associated with EBV infection (cohort 1) and with non-inflammatory disease  
conditions (cohort 2). Autoreactive antibody responses decreased following clinical resolution of 
acute IM symptoms. 
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Figure 1. Elevated myelin oligodendrocyte glycoprotein (MOG)-specific immunoglobulin G (IgG) 
responses during acute infectious mononucleosis (IM). Serum anti-MOG IgG reactivity of control 
and IM patient sera from cohort 1 (A) and cohort 2 (B) was detected at time of diagnosis. The 
positivity threshold, designated with a grey dotted line, was determined by three standard 
deviations above the mean of the control samples. (C) MOG-specific IgG responses disappear six 
months post  
IM diagnosis. 
 
 
Figure 2. Transient IgM autoreactivity during acute IM. HEp-2 immunofluorescence staining was 
performed with serum derived from IM patients and control subjects from both cohorts.  
(A) HEp-2 positive vimentin-like staining of one representative IM patient. (B) Summary table of 
elevated IgM reactivity to vimentin during acute IM observed in both cohorts. (C) and (D) ELISA 
detection of anti-vimentin IgM autoantibodies in IM patients was significantly elevated compared to 
controls in both cohorts. (E) Longitudinal samples collected from IM patients in cohort 1 revealed 
decrease in anti-vimentin IgM antibodies six months post diagnosis of acute IM. 
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During IM, activation of B lineage cells by EBV results in polyclonal immunoglobulin 
production and increased serum concentrations of immunoglobulin subclasses [12,13]. We found 
that IM patients from both cohorts showed higher total serum IgM and IgG levels as compared to 
controls  
(Figure 3A). Normalization of anti-vimentin IgM levels to total IgM concentrations resulted in a 
complete loss of significant differences for anti-vimentin IgM titers (Figure 3B). In contrast, anti-
MOG specific IgG responses were still detectable in a subset of three out of 35 patients with IM 
(9%), even after normalization to total IgG levels (Figure 3C). 
 
Figure 3. Vimentin-specific IgM and MOG-specific IgG autoantibody titers during acute IM 
following normalization to serum total IgM and serum total IgG. Total IgM and IgG (A) 
concentrations were measured in serum of IM patients and controls in both cohorts. Both IgM and 
IgG levels were significantly elevated during acute IM compared to controls. (B) Vimentin-specific 
IgM was normalized to total IgM concentrations, which led to loss of significant differences for  
vimentin-specific IgM titers between IM patients and controls in cohort 1 (left panel) and cohort 2 
(right panel). (C) MOG-specific IgG responses were normalized to total IgG concentrations. Despite 
normalization to total IgG, three IM patients in cohort 1 presented with MOG IgG reactivity above 
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the positivity threshold. The positivity threshold, designated with a grey dotted line, was set at 
three standard deviations above the mean of the respective control group. 
4. Discussion 
IgM antibodies specific for autoantigens have previously been described to occur frequently 
during acute IM, to be highest soon after onset and to disappear during convalescence [14–16]. 
These antibodies were shown to bind to a number of antigens present in EBV-transformed B cells 
and to partly cross-react with the glycine-alanine repeat domain of EBNA1 [15]. Vimentin, a major 
constituent of the intermediate filament family of proteins, serves scaffolding functions within 
mesenchymal cells and has been implicated in facilitating cell transformation and latent EBV-
derived membrane protein 1 (LMP1)-signaling during EBV infection [17,18] and IgM antibodies 
preferentially binding to vimentin and intermediate filaments have previously been detected in IM 
sera [19–21]. While we did not determine whether IgM antibodies to vimentin cross-react to EBV-
encoded antigen, the loss of significance for vimentin reactivity after normalization to total IgM 
indicates that the occurrence of these antibodies reflect random polyclonal B cell activation during 
acute IM or represent low-affinity IgM antibodies which disappear during affinity maturation of 
virus-specific B cells [15,16]. In contrast, the detection of IgG responses to MOG during acute IM 
implies that the producing B lineage cells underwent affinity maturation and acquired memory 
function. IgG responses to MOG, localized on the outermost surface of myelin within the CNS, are 
found in up to 40% of children with CNS demyelinating diseases such as ADEM, MS, NMOSD, 
isolated optic neuritis or transverse myelitis, but not in control subjects and only rarely in adults 
with these disorders [8,9]. 
Latent EBV infection is thought to confer B cell survival advantages during antigen-driven 
selection by mimicking signals of T cell help and B cell receptor engagement through LMP1 and 
LMP2 expression [22]. However, EBV infection of memory B cells in patients with acute IM does 
not result in increased frequencies of cells specific for autoantigens including MOG [23] arguing 
against a role for EBV in assisting the survival of autoreactive B cells. Instead, memory B cells can 
differentiate into antibody-secreting plasma cells in response to polyclonal stimuli, such as Toll-like 
receptor 9 (TLR9) ligation [24–26]. EBV DNA, readily available during acute IM, stimulates TLR9 
[27,28]. We infer from these data that IM-associated adjuvant effects such as TLR9 stimulation by 
EBV DNA might trigger polyclonal memory B cell stimulation and secretion of autoantigen-specific 
IgG. The occurrence of autoreactive IgG antibodies during symptomatic primary EBV infection 
could signal a propensity to develop autoimmune diseases in the future. 
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